We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+53.41%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$460M
AUM Growth
+$130M
Cap. Flow
-$89.1M
Cap. Flow %
-19.35%
Top 10 Hldgs %
94.26%
Holding
19
New
–
Increased
1
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
XFOR icon
X4 Pharmaceuticals
XFOR
+$598K

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$47M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$40.4M
3
STIM icon
Neuronetics
STIM
+$2.09M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$214K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$130M 28.22%
2,086,723
-988,102
-32% -$47M
ARVN icon
2
Arvinas
ARVN
$517M
$93.8M 20.38%
2,283,048
– –
SRRA
3
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$68.8M 14.94%
125,511
– –
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$50.1M 10.89%
914,625
-1,081,963
-54% -$40.4M
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$43.2M 9.39%
292,141
– –
ARAV
6
DELISTED
Aravive, Inc. Common Stock
ARAV
$12.9M 2.81%
946,423
-24,236
-2% -$214K
APTX
7
DELISTED
Aptinyx Inc. Common Stock
APTX
$11.3M 2.44%
3,290,079
– –
ALEC icon
8
Alector
ALEC
$167M
$11M 2.39%
639,569
– –
ITRM
9
DELISTED
Iterum Therapeutics
ITRM
$6.55M 1.42%
97,087
– –
TECX
10
Tectonic Therapeutic
TECX
$577M
$6.35M 1.38%
26,296
– –
STIM icon
11
Neuronetics
STIM
$126M
$4.67M 1.01%
1,039,285
-336,721
-24% -$2.09M
CHMA
12
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.65M 0.79%
735,700
– –
XFOR icon
13
X4 Pharmaceuticals
XFOR
$364M
$3.58M 0.78%
11,167
+1,667
+18% +$598K
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.86B
$3.54M 0.77%
141,000
– –
OBSV
15
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.44M 0.75%
900,501
– –
NERV icon
16
Minerva Neurosciences
NERV
$192M
$3.2M 0.69%
56,188
– –
CMRX
17
DELISTED
Chimerix, Inc.
CMRX
$2.74M 0.6%
1,350,000
– –
COGT icon
18
Cogent Biosciences
COGT
$6.76B
$1.29M 0.28%
448,886
– –
PDSB icon
19
PDS Biotechnology
PDSB
$38.1M
$311K 0.07%
117,242
– –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q4 2019 Portfolio in Review

As of Q4 2019, New Leaf Venture Partners held 19 positions worth $460M, up 39% from $331M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

New Leaf Venture Partners withdrew a net $89.1M in Q4 2019, reducing 4 holdings. Its largest reduction was Deciphera Pharmaceuticals, Inc. Common Stock, cutting an estimated $47M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, New Leaf Venture Partners added an estimated $598K to X4 Pharmaceuticals.

  • New Leaf Venture Partners added most to X4 Pharmaceuticals in Q4 2019, an estimated $598K increase.
  • New Leaf Venture Partners's biggest Q4 2019 reduction was Deciphera Pharmaceuticals, Inc. Common Stock, cutting an estimated $47M.
  • New Leaf Venture Partners's ten largest holdings make up 94% of its $460M portfolio in Q4 2019.
  • New Leaf Venture Partners opened 0 new positions and closed 0 in Q4 2019.
  • New Leaf Venture Partners's portfolio value rose 39% quarter-over-quarter to $460M.

Based on New Leaf Venture Partners's 13F filing for Q4 2019, filed 13 Feb 2020.